Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Santen Pharmaceutical Co. Ltd.

www.santen.com

Latest From Santen Pharmaceutical Co. Ltd.

EU Marketing Approval In Sight For 11 Drugs After CHMP OK; Thumbs Down For Two

The European Medicines Agency’s key scientific committee, the CHMP, has recommended for approval throughout Europe a total of 11 new drugs. Two medicines received a negative opinion from the committee and the marketing authorization application for one product has been withdrawn. A further eight products are set to receive indication extensions. The medicines that got positive opinions are likely to secure official approval within the next few months.

Approvals Europe

EU CHMP Decides On New Oncology Drugs & New Treatments for Mastocytosis, Atopic Dermatitis

The European Medicines Agency’s key scientific committee, the CHMP, is deciding this week whether a dozen or so new medicines that are in the final stages of the evaluation process should be approved for marketing across the EU. The committee will discuss 13 initial marketing authorization applications.

Approvals Regulation

Santen Readies India Expansion Via Centaur Alliance

Japan’s Santen appears set for a scale up in India via an alliance with Centaur Pharmaceuticals. The partners outline to Scrip the broad contours of the India plan.

Commercial Strategy

Deal Watch: Seattle Genetics' Controversial Collaboration With Immunomedics Topples

A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.

Deals M & A
See All

Company Information

  • Industry
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Santen Pharmaceutical Co. Ltd.
  • Senior Management
  • Akira Kurokawa, Pres. & CEO
  • Contact Info
  • Santen Pharmaceutical Co. Ltd.
    Phone: (81) 6-6321-7000
    4-20 Ofuka-cho, Kita-ku
    Osaka, 530-8552
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register